Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.34 +0.06 (+0.12%)
Streaming Delayed Price Updated: 2:04 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Balancing Dividends and Fundamentals: The Case of NASDAQ:SNY.
Is SANOFI-ADR (NASDAQ:SNY) suited for dividend investing? 
Via Chartmill
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing. 
Via Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry. 
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety
Sanofi's Earnings Outlook
Via Benzinga
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. 
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3. 
Via Benzinga
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
Via Benzinga
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access. Novo Nordisk's production shift raises concerns as diabetes cases rise,... 
Via Benzinga
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
NASDAQ:SNY stands out as a stock that provides good value for the fundamentals it showcases.
SANOFI-ADR (NASDAQ:SNY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. 
Via Benzinga
Exposures Product Safety
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
Why Sanofi Stock Flew Higher on Friday
No investor can ignore a crushing bottom-line beat and raised profitability guidance. 
Via The Motley Fool
Sanofi (SNY) Q3 2024 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
Via Benzinga
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
The company also hiked its profit outlook for the year and expects single-digit growth. 
Via Investor's Business Daily
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%. 
Via Benzinga
Markets Mixed Again; DECK, SKX Beat After The Bell
Over the past week or so of trading, we’ve seen the stock market begin to snarl at current valuation levels. 
Via Talk Markets
Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business
Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global OTC... 
Via Benzinga
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
Let's look beyond this piece of bad news from regulators. 
Via The Motley Fool
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European... 
Via Benzinga
France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block
Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 million euros as the French government weighs the sale due to national... 
Via Benzinga
Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R
France considers blocking Sanofi's $16 billion consumer division sale to U.S. firm CD&R, citing concerns over healthcare sovereignty, job protection, and local production amidst growing political... 
Via Benzinga
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
Via Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.